Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NKTR Drug delivery Company -- Ignore unavailable to you. Want to Upgrade?

To: david nordic who wrote (77)	7/24/2006 12:45:44 PM
From: Ian@SI	Read Replies (1) \| Respond to of 507

D., Unless I misread the PR, Hematide is not in NKTR's pipeline, it's in another company's. Purchasers of technology have the right to expect confidentiality. e.g. - INTC doesn't allow capital equipment companies to disclose its purchases from them. I see no reason why biotechs would want to provide an early indication of areas in which they are innovating. Unless and until royalties/license fees start rolling in, this will remain (rightly so IMO) a hidden asset not valued by the market. Ian